

# Pietro Mazzeo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4637744/publications.pdf>

Version: 2024-02-01

22  
papers

188  
citations

1039406

9  
h-index

1125271

13  
g-index

22  
all docs

22  
docs citations

22  
times ranked

268  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry. <i>IJC Heart and Vasculature</i> , 2020, 27, 100486.	0.6	33
2	Difficult-to-control hypertension: identification of clinical predictors and use of ICT-based integrated care to facilitate blood pressure control. <i>Journal of Human Hypertension</i> , 2018, 32, 467-476.	1.0	22
3	The Italian version of the quick mild cognitive impairment (Qmci-I) screen: normative study on 307 healthy subjects. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 353-360.	1.4	20
4	Vitamin D, parathyroid hormone and cardiovascular risk. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 62-66.	0.6	18
5	Serum Uric Acid and Left Ventricular Mass in Essential Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 570000.	1.1	14
6	Liver disease and heart failure. <i>Panminerva Medica</i> , 2020, 62, 26-37.	0.2	14
7	Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1157-1164.	1.3	13
8	Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	11
9	New Targets in Heart Failure Drug Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665797.	1.1	10
10	Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. <i>ESC Heart Failure</i> , 2022, 9, 2909-2917.	1.4	10
11	Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan. <i>Acta Cardiologica</i> , 2021, , 1-6.	0.3	7
12	Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure. <i>Clinical Physiology and Functional Imaging</i> , 2021, 41, 505-513.	0.5	7
13	Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation. <i>Thrombosis Research</i> , 2020, 195, 16-20.	0.8	5
14	The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 341-351.	1.3	3
15	Multivessel spontaneous coronary artery dissection and Crohn's disease. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, e26-e28.	0.6	1
16	25-year Atrial remodelling in patients affected by chronic heart failure in therapy with sacubitril/valsartan. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
17	63-year Peripheral endothelial function in patients affected by pulmonary hypertension. Relationship between endothelial function, haemodynamic parameters, and therapy response. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
18	37-year Prognostic role of the lung ultrasound in the acute coronary syndrome. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0

#	ARTICLE	IF	CITATIONS
19	Biventricular evaluation of gliflozines effects in chronic heart failure patients function (begin-HF) Tj ETQq1 1 0,784314 ggBT /Over	0.0	0
20	Deformation imaging by strain in chronic heart failure over sacubitrilâ€“valsartan: a multicentre echocardiographic registry (discover)â€”ARNI. European Heart Journal Supplements, 2021, 23, .	0.0	0
21	Gliflozins and ventricular function in patients affected by chronic heart failure with diabetes mellitus. European Heart Journal Supplements, 2021, 23, .	0.0	0
22	Right ventricular function in patient with heart failure with reduced ejection fraction and sacubitril/valsartan treatment. European Heart Journal Supplements, 2021, 23, .	0.0	0